---
document_datetime: 2025-02-21 11:00:21
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/omvoh-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: omvoh-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.431494
conversion_datetime: 2025-12-18 22:33:40.793266
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Omvoh

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| X/0006/G             | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 12/12/2024                          | 12/02/2025                                  | SmPC, Labelling and PL           |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                  | (excipients) of the finished product - Other excipients - Change that is supported by a bioequivalence study B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)   |            |     |                        |                                   |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|-----------------------------------|
| IB/0009          | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 08/01/2025 |     | SmPC, Labelling and PL |                                   |
| IB/0008          | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 15/11/2024 | n/a |                        |                                   |
| PSUSA/49/20 2403 | Periodic Safety Update EU Single assessment - mirikizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 31/10/2024 | n/a |                        | PRAC Recommendation - maintenance |
| PSUSA/49/20 2309 | Periodic Safety Update EU Single assessment - mirikizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/04/2024 | n/a |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0005/G   | This was an application for a group of variations.   | 05/04/2024   | n/a   |
|-------------|------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

| IB/0003   | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                | 22/12/2023   | 19/12/2024   | SmPC   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|
| IB/0002   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 30/08/2023   | n/a          |        |
| N/0001    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                       | 28/07/2023   | 19/12/2024   | PL     |